ECSP22089507A - Conjugado anticuerpo-fármaco, método de preparación del mismo y uso del mismo - Google Patents

Conjugado anticuerpo-fármaco, método de preparación del mismo y uso del mismo

Info

Publication number
ECSP22089507A
ECSP22089507A ECSENADI202289507A ECDI202289507A ECSP22089507A EC SP22089507 A ECSP22089507 A EC SP22089507A EC SENADI202289507 A ECSENADI202289507 A EC SENADI202289507A EC DI202289507 A ECDI202289507 A EC DI202289507A EC SP22089507 A ECSP22089507 A EC SP22089507A
Authority
EC
Ecuador
Prior art keywords
antibody
drug conjugate
preparation
composition
cldn
Prior art date
Application number
ECSENADI202289507A
Other languages
English (en)
Inventor
Tongtong Xue
Qiang Tian
Liang Xiao
Jingyi Wang
Llc Popsockets
Dengnian Liu
Cheng Wang
Original Assignee
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Kelun Biotech Biopharmaceutical Co Ltd filed Critical Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Publication of ECSP22089507A publication Critical patent/ECSP22089507A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se relaciona un conjugado de anticuerpo-fármaco anti-CLDN 18.2, método de preparación y uso del mismo. El conjugado de anticuerpo-fármaco y la composición del mismo es capaz de unirse eficazmente a CLDN 18.2 e inhibir el crecimiento de tumores positivos para Claudin 18.2. También se relaciona una composición farmacéutica que comprende el conjugado de anticuerpo-fármaco o la composición, y el uso de la composición farmacéutica en la preparación de un medicamento para prevenir y/o tratar tumores.
ECSENADI202289507A 2020-05-15 2022-11-21 Conjugado anticuerpo-fármaco, método de preparación del mismo y uso del mismo ECSP22089507A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010410633 2020-05-15

Publications (1)

Publication Number Publication Date
ECSP22089507A true ECSP22089507A (es) 2023-02-28

Family

ID=78525267

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202289507A ECSP22089507A (es) 2020-05-15 2022-11-21 Conjugado anticuerpo-fármaco, método de preparación del mismo y uso del mismo

Country Status (18)

Country Link
US (1) US20230338565A1 (es)
EP (1) EP4151235A4 (es)
JP (2) JP7407973B2 (es)
KR (1) KR20230012000A (es)
CN (1) CN115715202B (es)
AU (1) AU2021270940A1 (es)
CA (1) CA3178406A1 (es)
CL (2) CL2022003170A1 (es)
CO (1) CO2022016208A2 (es)
CR (1) CR20220580A (es)
DO (1) DOP2022000251A (es)
EC (1) ECSP22089507A (es)
GE (2) GEP20257719B (es)
IL (1) IL298184A (es)
JO (1) JOP20220306A1 (es)
MX (1) MX2022014332A (es)
PE (1) PE20230373A1 (es)
WO (1) WO2021228141A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118201932A (zh) * 2021-12-02 2024-06-14 四川科伦博泰生物医药股份有限公司 一种药物-接头偶联物的制备方法
WO2023143208A1 (zh) * 2022-01-26 2023-08-03 苏州宜联生物医药有限公司 一种药物连接体偶联物的制备方法
CA3261633A1 (en) * 2022-07-14 2025-04-25 Medilink Therapeutics (Suzhou) Co., Ltd. ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD AND USE
CN119907693A (zh) * 2022-08-02 2025-04-29 诺纳生物（苏州）有限公司 Msln抗体药物偶联物
US20260001891A1 (en) 2022-11-22 2026-01-01 Keymed Biosciences (Chengdu) Co., Ltd. Fused ring compound, conjugate thereof and use thereof
AU2024224458A1 (en) * 2023-02-24 2025-09-04 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Use of drug conjugate in treatment of tumor disease and method
JP2026507705A (ja) * 2023-03-02 2026-03-04 マルティテュード・セラピューティクス・インコーポレイテッド 抗体薬物複合体、医薬組成物及びその使用
CN119212734A (zh) * 2023-04-27 2024-12-27 石药集团巨石生物制药有限公司 一种抗体药物偶联物
WO2024222841A1 (zh) * 2023-04-27 2024-10-31 石药集团巨石生物制药有限公司 一种抗体药物偶联物
EP4461317A1 (en) * 2023-05-12 2024-11-13 Emergence Therapeutics GmbH Antibody-drug conjugates comprising an anti-nectin-4 antibody and belotecan or a derivative thereof
WO2024255880A1 (en) * 2023-06-16 2024-12-19 Fortvita Biologics (Singapore) Pte. Ltd. A method for treatment of solid tumors with an antibody-drug conjugate targeting claudin 18.2
CN117327182B (zh) * 2023-09-19 2024-06-04 上海交通大学医学院附属仁济医院 Cldn18.2单域抗体探针的制备方法及应用
WO2025106278A1 (en) 2023-11-17 2025-05-22 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates
WO2026086855A1 (zh) * 2024-10-25 2026-04-30 石药集团巨石生物制药有限公司 一种靶向cdcp1的抗体药物偶联物及其用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP1997832A1 (en) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
US9056092B2 (en) 2011-12-02 2015-06-16 Ethicon, Inc. Hemostatic bioabsorbable device with polyethylene glycol binder
WO2013174404A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
AU2013360335B2 (en) * 2012-12-13 2017-12-07 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
KR102236367B1 (ko) 2013-07-26 2021-04-05 삼성전자주식회사 DARPin을 포함하는 이중 특이 키메라 단백질
US10323095B2 (en) 2014-03-17 2019-06-18 Mitsubishi Tanabe Pharma Corporation Antibody-fynomer conjugates
WO2016165762A1 (en) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
CA3030257A1 (en) 2016-07-08 2018-01-11 Carsgen Therapeutics Co., Ltd. Antibody for anti-claudin 18a2 and use thereof
CN119241554A (zh) 2017-12-15 2025-01-03 四川科伦博泰生物医药股份有限公司 生物活性物偶联物及其制备方法和用途
CN111447939B (zh) * 2018-01-30 2024-07-12 四川科伦博泰生物医药股份有限公司 制备偶联物的方法
CN111542324B (zh) * 2018-02-11 2023-09-12 四川科伦博泰生物医药股份有限公司 细胞毒性剂及其偶联物、其制备方法及用途
BR112020014591A2 (pt) * 2018-03-14 2020-12-01 Beijing Xuanyi Pharmasciences Co., Ltd. anticorpos anticlaudina 18.2
CN111110862A (zh) * 2018-11-01 2020-05-08 上海健信生物医药科技有限公司 抗cldn18．2抗体的药物偶联体及其制备方法和用途
EP3824096A4 (en) * 2018-07-18 2022-04-20 AskGene Pharma Inc. NOVEL ANTIBODIES AND METHODS FOR THE PRODUCTION AND USE THEREOF
EP3826612A4 (en) * 2018-07-25 2022-09-14 Accurus Biosciences, Inc. NOVEL CLDN-18.2-SPECIFIC MONOCLONAL ANTIBODIES AND METHODS OF USE
CN113166246B (zh) 2018-12-28 2024-10-18 四川科伦博泰生物医药股份有限公司 一种抗体及其用途
US20230192903A1 (en) * 2020-05-29 2023-06-22 Wuhan Yzy Biopharma Co., Ltd. Bispecific antibody against cldn18.2 and cd3

Also Published As

Publication number Publication date
GEP20257719B (en) 2025-01-27
JP2023525120A (ja) 2023-06-14
PE20230373A1 (es) 2023-03-06
CA3178406A1 (en) 2021-11-18
CL2024002956A1 (es) 2025-01-24
IL298184A (en) 2023-01-01
KR20230012000A (ko) 2023-01-25
CR20220580A (es) 2023-04-11
JOP20220306A1 (ar) 2022-11-10
GEAP202416114A (en) 2024-08-26
MX2022014332A (es) 2022-12-13
JP7734178B2 (ja) 2025-09-04
US20230338565A1 (en) 2023-10-26
AU2021270940A1 (en) 2022-12-15
EP4151235A1 (en) 2023-03-22
JP7407973B2 (ja) 2024-01-04
JP2024037960A (ja) 2024-03-19
CO2022016208A2 (es) 2023-02-27
DOP2022000251A (es) 2023-04-16
CL2022003170A1 (es) 2023-05-19
EP4151235A4 (en) 2025-08-06
CN115715202B (zh) 2025-11-04
WO2021228141A1 (zh) 2021-11-18
CN115715202A (zh) 2023-02-24

Similar Documents

Publication Publication Date Title
DOP2022000251A (es) Conjugado anticuerpo-fármaco, método de preparación del mismo y uso del mismo
CO2023013050A2 (es) Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas
CL2024003232A1 (es) Compuestos derivados de heteroarilo y uso para tratar el dolor.
MX2021001807A (es) Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma.
CL2024003231A1 (es) Compuestos derivados de heteroarilo y uso para tratar el dolor.
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
AR119158A1 (es) Tratamientos de angioedema hereditario
AR045016A1 (es) Derivados de 5-carbamimidoi-2-metilsulfaniltiofen-3-sulfonil como inhibidores conjugados de la cascada de complemento y su uso en el tratamiento de enfermedades.
GEP20267876B (en) Anti-nectin-4 antibody, conjugate including same, and application thereof
MX2024008461A (es) Metodos para tratar trastornos linfoproliferativos malignos.
BR112021024491A8 (pt) Composição imunogênica, e, método para prevenir, tratar ou melhorar uma infecção, doença ou condição
CL2022003507A1 (es) Composición y método para tratar el dolor crónico
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
MX2023012095A (es) Inhibidores de hdac6 para el uso en el tratamiento de la miocardiopatía dilatada.
BR112022000229A2 (pt) Composição para uso no tratamento da perda de cabelo
CR20220374A (es) Métodos de tratamiento de la esplenomegalia
BR112022010702A2 (pt) Macrociclos para uso no tratamento de doenças
CL2024002379A1 (es) Composición farmacéutica y que comprende derivados de difenildiazol métodos de uso
BR112022009881A2 (pt) Inibidores de caspase 6 e usos dos mesmos
CO2025018532A2 (es) Un método para el tratamiento de tumores sólidos con un conjugado anticuerpo-fármaco dirigido a claudina 18.2
BR112022000155A2 (pt) Composição inibidora da micromolécula pi4kiiia, seu método de preparação, e uso da mesma
MX2023010545A (es) Inhibidores de integrinas alfa v beta 6 y alfa v beta 1 y usos de los mismos.
MX2025004545A (es) 3,4 a, 5, 7, 8, 8a-hexahidro-4h-tiopirano [4,3-d] pirimidin-4-onas 2-sustituidas para el tratamiento de heridas
MX2022005199A (es) Inhibidores de ssao y uso de los mismos.
MX2025015102A (es) Formulacion que comprende un conjugado anticuerpo-farmaco dirigido a claudina 18.2, metodo para su preparacion y uso